AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01337570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaginal Ring containing no drug substance
Study NCT01337570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine
Study NCT04264000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma
Description: Ultrasound-guided 3cc PRP injection between medial epicondyle and ulnar nerve
Study NCT04264000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% dextrose
Description: Ultrasound-guided 3cc 5% dextrose injection between medial epicondyle and ulnar nerve
Study NCT00181753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stable isotope tracer study
Description: 7 hours primed constant infusion of stable isotope tracer study
Study NCT03107117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Counseling
Description: two computer counseling online programs for a teen and a parent
Study NCT03107117 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: A referral for substance use counseling
Study NCT03573063 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Androgen metabolism after starvation
Description: The 20 women will all undergo the same process of starvation for 48 hours. During this time three blood samples and three 24-hours urine samples will be collected. At baseline, the investigators will draw blood, perform a pregnancy test and collect the 24 hours urine as well as a spot urine.~Then the 48 hours starvation starts and two blood and two 24 hours urine samples and spot urines will be collected after 24 and 48 hours in the morning. After the third visit the study is completed for the participant.
Study NCT03423277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easy Stretch Toolkit
Description: Study the use of novel intraoral tools for management of facial burns and other facial disorders
Study NCT03221777 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)
Description: The ZIO XT Patch (http://www.irhythmtech.com/zio-solution/zio-patch/) is an ultra-portable wearable adhesive patch monitor that provides continuous single-lead ECG recording for up to 14 days. It has been cleared by the FDA for arrhythmia detection and is in current clinical use in the U.S.\[87\]. It will be used in this study under an investigational testing authorization by Health Canada. The ZIO XT Patch is a single-use device worn over the left pectoral region with a skin adhesive (Figure 4). Its small, lightweight, water-resistant, patch-based design has advantages for patients compared with traditional ECG screening methods (e.g. Holter, event loop recorders, mobile outpatient telemetry systems), which are all more cumbersome and require detachable wired leads, two or more removable skin contact electrodes, plus separate recording units (+/- smartphone attachment).
Study NCT02336438 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucomannan
Description: Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
Study NCT04001400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20mg bid
Description: Rabeprazole 20mg tablet b.i.d.
Study NCT04001400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole 20mg qd
Description: Rabeprazole 20mg tablet q.d.
Study NCT01932684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath-Stacking
Description: We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
Study NCT01932684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Description: We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
Study NCT01932684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5000 Voldyne ® Sherwood Medical, USA
Study NCT01932684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone face mask
Study NCT04397380 — intervention group
Intervention type: DEVICE
Intervention: Thermography
Description: Measure Temperature using Thermal Camera
Study NCT04397380 — intervention group
Intervention type: DEVICE
Intervention: Tympanic Temperature
Description: Measure Temperature using Tympanic Temperature
Study NCT01326442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low glycemic diet
Description: a low glycemic diet, calorie restricted with exercise sessions 3 times per week
Study NCT01326442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low glycemic diet
Description: a low glycemic diet, calorie restricted with exercise sessions 3 times per week
Study NCT01326442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D omega-3
Description: 2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
Study NCT02797821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asfotase alfa
Study NCT01337063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentored medication reconciliation quality improvement
Description: Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls.
Study NCT04252612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: SymlinPen is a 2.7 ml; 1000 mcg/ml disposable injector pen that delivers 60 or 120 mcg doses of Pramlintide.
Study NCT03632252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered ankle prosthesis
Description: This device is a custom designed ankle prosthesis. Motors control force on the device through cables but are not worn by the person.
Study NCT03800862 — intervention group
Intervention type: DEVICE
Intervention: CT-FFR and CTP
Description: Those who agree to participate will be scheduled to have the CT-FFR and CTP performed within sixty days of the initial Coronary CTA procedure. A CTA will be performed at rest for FFR. The patient will then take approximately a 30 min break. Regadenoson will then be administered and the dynamic CT procedure will be done for perfusion.
Study NCT03057756 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Km+ Mfx+ Pto + H + Cfz +E+Z
Description: Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide
Study NCT00811460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: sc for 4 days
Study NCT00811460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 300micrograms/day sc for 2 days
Study NCT00811460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 800 micrograms/day sc for 2 days
Study NCT04039932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLAME
Description: The FLAME intervention trains pairs of faith leaders and community health workers and deploys them to conduct behavior change outreach in their communities.
Study NCT03493646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: 75mg/m2 per day for 7 days of each 28 day cycle. Cycles 1-6
Study NCT03493646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: 100 mg BID for the first 21 days of each 28-day treatment cycle (cycles 7-8). The dose should be increased from cycle 9 onwards to 150mg BID for the first 21 days of each 28-day treatment cycle (cycles 9-12) in the absence of Grade 3 or 4 AE. If 2 or more cycles are tolerated at this dose, further increments are permitted for patients with Stable Disease or if clinically indicated in consultation with the coordinating investigator as per the study dose modification schedule.
Study NCT01518712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
Study NCT05181488 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy, IORT
Description: A dose of 10 Gy is prescribed to be irradiated at a depth of 5 mm from the surface of the applicator, and the radiation oncologist determines the exact irradiation time. The irradiation time may take 20 to 60 minutes depending on the size of the applicator, and the exact irradiation time is calculated after checking the quality assurance of the radiation generator before treatment every day.
Study NCT05321290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Therapy Program
Study NCT03880357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Scalp Suspension 0.064%;0.0005%
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
Study NCT03880357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex®
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
Study NCT03880357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo topical suspension
Description: applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
Study NCT02455167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprivir (SMV)
Description: Experimental Single arm study. All participants will get the same treatment.
Study NCT01518712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Study NCT02455167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)
Description: Experimental Single arm study. All participants will get the same treatment.
Study NCT02455167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Experimental Single arm study. All participants will get the same treatment.
Study NCT01966146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echography GE Healthcare Vivid E9
Description: Echography GE Healthcare Vivid E9
Study NCT06184802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU+Multisensory room
Description: Multisensory room session included exercises in different interaction areas that allow to make up a multisensory experience where the patient can freely perform in different directions experimenting combinations of play
Study NCT06184802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: neuro-psychomotor training promotes a better organization of global motor skills, improve hand-eye coordination, promote the development of language as communication, enriching representation and symbolization skills.
Study NCT02712788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Study NCT02712788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02485015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Killer Cells
Description: Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
Study NCT02485015 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
Study NCT02485015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
Study NCT02286609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
Study NCT02017184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Noninvasive core temperature thermistor
Study NCT00928967 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b, (Betaseron BAY86-5046)
Description: The cohort included is described in section 8.5 (inclusion criteria)
Study NCT04104347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Description: Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz \& Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.
Study NCT04104347 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Support group
Description: Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
Study NCT03166748 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Nitrate in Polycarboxylate cement
Description: The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity
Study NCT03166748 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate in Polycarboxylate cement
Description: The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity
Study NCT03060902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills
Description: DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
Study NCT04473560 — intervention group
Intervention type: DEVICE
Intervention: Catheter-directed thrombectomy
Description: Using common femoral venous access the pigtail diagnostic catheter will be placed into the main pulmonary artery and an initial pulmonary angiogram will be performed to demonstrate the location and extent of thrombi in pulmonary arteries. Then pulmonary arterial pressures will be measured. Subsequently an Indigo catheter (Penumbra, Alameda, California) will be placed and a direct-aspiration first-pass technique will be performed purposefully to attach a large thrombus to the catheter tip by suction and then pull it out through the sheath. The decision to terminate the intervention will be at operator's discretion after careful evaluation of hemodynamic parameters (restoration of the systolic blood pressure≥100 mmHg, heart rate \<100/min), improvement of arterial blood saturation≥ 92%, practicable clot burden reduction and total amount of aspirated blood (no more than 300 ml).
Study NCT04201704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balanced crystalloid solution volume administration
Description: Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.
Study NCT04201704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution volume administration
Description: Maintenance and bolus fluid volumes of balanced isotonic crystalloid solution administered based on arm.
Study NCT04201704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Packed Erythrocytes Units, Blood Product Unit volume
Description: For patients designated as Bleeding, where hemoglobin \<7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
Study NCT04201704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Packed Erythrocytes Units, Blood Product Unit volume
Description: For patients designated as Bleeding, where hemoglobin \<7 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.
Study NCT01797510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Based Health Coaching
Study NCT03440255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: TaVNS will be applied by the TENS 7000 device. The stimulation was set according the group of treatment: (GAD: 20Hz-80µs), (CP: 5Hz-200 µs), (IBS: 3Hz-250µs).~The current intensity was individually established under the pain threshold .The stimulus generates an continous asymmetric biphasic waveform. Ear clip electrodes were plugged in the concha area of the left ear. The stimulation will last 30 min per session (total=8)
Study NCT04342182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.~Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products
Study NCT00887146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concomitant temozolomide (TMZ)
Description: 75 mg/m\^2, orally daily
Study NCT04201704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma volume
Description: For patients designated as Bleeding, where International Normalized Ratio (INR) > 1.5 then patient will be transfused 10 mL/kg up to 250 mL/transfusion. If patient is hypovolemic with clinician discretion transfuse 20 mL/kg.